Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA…
All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs)BION-1301 continues…